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Abstract
Background
Diagnosis of tuberculosis in people living with HIV is challenging due to non-specific clinical
presentations and inadequately sensitive diagnostic tests. The WHO recommends screen-
ing using a clinical algorithm followed by rapid diagnosis using the Xpert MTB/RIF assay,
and more information is needed to evaluate these recommendations in different settings.
Methods
From August 2012 to September 2013, consecutive adults newly diagnosed with HIV in
Bamenda, Cameroon, were screened for TB regardless of symptoms by smear microscopy
and culture; the Xpert MTB/RIF assay was performed retrospectively. Time to treatment
and patient outcomes were obtained from routine registers.
Results
Among 1,149 people enrolled, 940 (82%) produced sputum for lab testing; of these, 68%
were women, the median age was 35 years (IQR, 28–42 years), the median CD4 count was
291cells/μL (IQR, 116–496 cells/μL), and 86% had one or more of current cough, fever,
night sweats, or weight loss. In total, 131 people (14%, 95% CI, 12–16%) had sputum cul-
ture-positive TB. The WHO symptom screening algorithm had a sensitivity of 92% (95%CI,
86–96%) and specificity of 15% (95%CI, 12–17%) in this population. Compared to TB cul-
ture, the sensitivity of direct smear microscopy was 25% (95% CI, 18–34%), and the sensi-
tivity of Xpert was 68% (95% CI, 58–76); the sensitivity of both was higher for people
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reporting more symptoms. Only one of 69 people with smear-negative/culture-positive TB
was started on TB treatment prior to culture positivity. Of 71 people with bacteriologically-
confirmed TB and known outcome after 6 months, 13 (17%) had died, including 11 people
with smear-negative TB and 6 people with both smear and Xpert-negative TB.
Conclusions
Use of the most sensitive rapid diagnostic test available is critical in people newly diagnosed
with HIV in this setting to maximize the detection of bacteriologically-confirmed TB. How-
ever, this intervention is not sufficient alone and should be combined with more comprehen-
sive clinical diagnosis of TB to improve outcomes.
Introduction
Detecting tuberculosis in people with the disease is often a significant challenge since screen-
ing algorithms are typically non-specific and the currently available rapid diagnostic tools are
inadequately sensitive. These challenges are compounded in people living with HIV, who pres-
ent with more highly variable clinical manifestations of TB than people without HIV.[1–3] As
a result, the mortality rate among people with HIV and TB co-infection is high, and many of
these people die without ever being diagnosed with TB.[4]
To improve TB case finding among people living with HIV, in 2011 the World Health
Organization (WHO) recommended regular screening using a clinical algorithm.[5,6] In a
high TB prevalence setting, a person living with HIV presenting with current cough, fever,
night sweats and/or weight loss is to be evaluated further to either identify TB or make another
diagnosis and initiate isoniazid preventive therapy for TB. In most settings, smear microscopy
is the only widely available laboratory tool for diagnosis of TB, and although it is rapid and
inexpensive, it has poor sensitivity, particularly in people living with HIV.[7–9] Since 2010, the
WHO has recommended replacing smear microscopy with the Xpert MTB/RIF assay,[10]
which is rapid and has better sensitivity but is also significantly more expensive than micros-
copy. The performance of the recommended WHO symptom screen combined with the Xpert
MTB/RIF assay testing has been assessed in various settings.[11–13]. The development of opti-
mal local algorithms for TB diagnosis depends on setting-specific factors, including disease
burden, resource availability, and public health priorities.[14,15]
Cameroon has a high estimated incidence of TB/HIV (70 per 100,000), a modest estimated
TB case detection rate (55%), and a low coverage of testing with WHO-recommended rapid
diagnostics for TB (Xpert MTB/RIF assay) as an initial diagnostic test (<10%).[16] The perfor-
mance of the current WHO recommendations for symptom screening and Xpert MTB/RIF
testing among people living with HIV have not yet been evaluated in this setting. The aim of
this study was to assess the burden of TB among people newly diagnosed with HIV at a large
testing and treatment center in Cameroon and to compare the performance of the WHO-rec-
ommended clinical screening algorithm and TB diagnostic methods in this population.
Methods
Study setting and methods
This study was conducted at the Treatment Center for HIV/AIDS at the Bamenda Regional
Hospital and at the Tuberculosis Reference Laboratory Bamenda. The Treatment Center
TB in people newly diagnosed with HIV in Cameroon
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served as the largest of 18 such centers in the Northwest Region of Cameroon at the time of
the study; currently there are a total of 81 HIV care and treatment centers serving this region.
This center reported ~1,200 newly diagnosed HIV cases each year in 2012 and 2013, which
represented approximately one third of all HIV cases diagnosed in the Northwest geographical
region during this time. The study was planned to include 780 participants with TB lab testing
results, from whom there would be an estimated 69 TB cases based on a TB prevalence of 8.5%
from a meta-analysis including people attending HIV care and treatment centers.[1] The
Tuberculosis Reference Laboratory Bamenda is an accredited facility (SANAS accredited med-
ical laboratory, No. M0593). The laboratory works with the National TB Program and serves
four regions of the country. This study was approved by the National Ethics Committee of
Cameroon.
Consecutive adults with newly-diagnosed HIV infection presenting at the HIV testing and
ART treatment center at the Bamenda Regional Hospital from August 6, 2012 to September 3,
2013 were screened for eligibility and invited to participate. Participants were recruited regard-
less of the presence or absence of symptoms or clinical suspicion of TB. People were included
if they had a first diagnosis of HIV within the past month, were18 years of age and provided
written informed consent; people were excluded if they were currently on TB treatment. After
enrollment, the participants completed a standardized interview, underwent a physical exam
to aid in WHO staging, provided blood for CD4 testing, and were instructed on how to pro-
duce two sputum specimens for TB lab testing, one on the spot and one early in the morning.
People diagnosed with bacteriologically-confirmed TB were followed up in the routine ser-
vice. The time to initiation of treatment and vital status at 6 months were recorded from the
patient records.
Laboratory methods
For each specimen, a smear was prepared directly from sputum and examined for acid-fast
bacilli by fluorescence microscopy, then the sputum was processed using the N-acetyl-L-cyste-
ine–NaOH (NALC-NaOH) method.[17] From the re-suspended pellet, a concentrated smear
was prepared and examined for acid-fast bacilli by fluorescence microscopy, 0.5mL was cul-
tured on mycobacterial growth indicator tubes (MGIT, BD Diagnostic Systems, Sparks, MD,
USA) using the BACTEC MGIT 960 system, and ~0.1mL was cultured on each of two slopes
of Lo¨wenstein-Jensen media. Cultures were read by lab technicians who did not have knowl-
edge of microscopy results. Cultures positive for acid-fast bacilli were tested by MPT64 antigen
detection (Standard Diagnostics, Korea), and those that were positive were identified as M.
tuberculosis complex. The remainder of the processed sputum was stored at -20˚C because the
Xpert assay was not available in our setting at the time of the study. The remainder from the
morning sputum specimen from those with culture-confirmed TB was tested retrospectively
using the Xpert MTB/RIF assay (Cepheid, Sunnyvale, USA). Retrospective Xpert testing was
only possible for 108 of the 131 specimens from people with culture-positive TB because some
specimens were inadvertently discarded.
Definitions
People with one or more sputum culture positive for M. tuberculosis complex were defined as
having tuberculosis, while those with at least one negative culture and no positive cultures
were defined as not having tuberculosis. Sputum smears with a grade of scanty, 1+, 2+ or 3
+ were classified as smear-positive; for those providing two sputum specimens, the higher
result was used to classify by smear-grade and as smear-positive or smear-negative. Partici-
pants were followed up by the routine HIV and TB services. Laboratory and TB treatment
TB in people newly diagnosed with HIV in Cameroon
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registers were reviewed for patients diagnosed with TB to determine vital status from clinical
outcome (cured on treatment, died before or during treatment, lost to follow-up before or dur-
ing treatment, transferred out or referred to another site for treatment).
Data analysis
Data was entered into an EpiData (www.epidata.dk) database from the study files and labora-
tory registers and validated by double entry and comparison. Participants were characterized
using simple descriptive statistics. The sensitivity of microscopy and Xpert MTB/RIF assay
were calculated and stratified by number of symptoms reported, WHO stage, CD4 cell count
and patient outcome. Proportions were compared using the χ2 or Fisher’s exact test as appro-
priate. EpiData was used for analysis. The STROBE recommendations were followed for
reporting these data.[18]
Results
Of 1,149 people who were enrolled and screened for TB, 940 (82%) produced at least one spu-
tum specimen for laboratory testing (902 of these produced two sputum specimens), and 131
had at least one sputum culture positive for M. tuberculosis complex (Fig 1). Of those with cul-
ture-positive TB, the Xpert MTB/RIF assay was performed retrospectively on the remaining
sputum for 108 (82%). Among these, 71 people (66%) had a known vital status at six months.
Among those tested for TB (Table 1), 68% were women, the median age was 35 years (IQR,
28–42 years), and the median CD4 count was 291cells/μL (IQR, 116-496cells/mL). In this pop-
ulation, 86% of participants had a positive WHO symptom screen, including 48% with current
cough, 23% with fever, 42% with night sweats, and 63% with weight loss. These characteristics
were similar among the 209 people who did not produce sputum for testing, of whom 70%
were women, with median age of 32 years (IQR, 27–41 years), median CD4 count of 289 cells/
μL (IQR, 108–512 cells/μL) and 86% with a positive WHO symptom screen of current cough,
fever, night sweats and/or weight loss.
Fig 1. Flow diagram showing the study population.
https://doi.org/10.1371/journal.pone.0199634.g001
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Overall, the prevalence of sputum culture-positive TB in this population was 13.9% (95%
CI, 11.9–16.3%). As in Table 2, the prevalence was higher among men than women (20% vs.
11%, p<0.001). The prevalence varied greatly when stratified by CD4 count, from 7% for peo-
ple with a CD4>350 cells/uL to 26% among those with CD4<100 cells/uL. For people report-
ing any one of cough, fever, night sweats or weight loss, the prevalence was 15% (95% CI, 13–
18%), while for those reporting none of these symptoms, it was 8% (95% CI, 4–14%). Among
people reporting any cough, the TB prevalence was 20%, and this was similar for those report-
ing a cough for more or less than 2 weeks (22% vs. 18%, respectively).
In these people with newly-diagnosed HIV infection, the WHO screening algorithm (cur-
rent cough, fever, night sweats and/or weight loss) had a sensitivity of 92% (95% CI, 86–96%),
specificity of 15% (95% CI, 12–17%), positive predictive value of 15% (95% CI, 14–17%), and
negative predictive value of 92% (95% CI, 86–96%) to detect TB when compared with the cul-
ture as the reference standard.
Of the 131 people with culture-confirmed TB, the sensitivity of direct smear microscopy
was 24% (95% CI, 18–32%), the sensitivity of concentrated smear microscopy was 35% (95%
CI, 28–44%), the sensitivity of solid culture was 81% (95% CI, 73–87%) and the sensitivity of
liquid culture was 98% (95% CI, 94–99%). The final contamination rate on solid culture was
4.3% and on liquid culture was 3.3%, and there were no specimens with all cultures contami-
nated. Of the 131 people with culture-confirmed TB, 85 (65%) had two specimens culture posi-
tive, 38 (29%) had one of two specimens culture positive, and 8 (6%) had only one specimen
submitted and culture positive (S1 Table).
For retrospective testing of Xpert on a single specimen, the sensitivity of direct and concen-
trated smear microscopy for the 108 specimens included was similar to that for the 131 people
with culture confirmed TB (25% vs. 24% and 36% vs. 35%, respectively). The sensitivity of
Xpert compared to culture-positive TB was 68% (95% CI, 58–76%); the Xpert sensitivity was
97% among the 39 smear-positive specimens and 51% among the 69 smear-negative speci-
mens. Of the 73 Xpert positive specimens, 20 (27%) had an Xpert grade of very low, 27 (37%)
low, 19 (26%) medium, and 7 (10%) high positive, (S1 Table).
Table 1. Characteristics of 940 people newly diagnosed with HIV for whom TB culture results were available,
according to whether TB was diagnosed.
Characteristic All participants No bacteriologically-
confirmed TB
Bacteriologically-
confirmed TB
(n = 940) (n = 809) (n = 131)
Age
Age, median (IQR), years 35 (28–42) 34 (28–42) 36 (29–43)
Sex
Female, % (n) 68 (641) 70 (569) 55 (72)
Male, % (n) 32 (299) 30 (240) 45 (59)
WHO stage (n = 821)
1–2, % (n) 66 (539) 70 (490) 40 (49)
3–4, % (n) 34 (282) 30 (209) 60 (73)
CD4 count (cells/μL)
CD4, median (IQR) 291 (116–496) 315 (139–511) 143 (42–276)
Symptoms
Positive WHO screen, % (n) 86 (812) 85 (691) 92 (121)
 119 people did not have a WHO stage recorded. IQR: interquartile range
https://doi.org/10.1371/journal.pone.0199634.t001
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As shown in Table 3, for those people reporting all four symptoms, the sensitivity of micros-
copy and Xpert was higher, 61% and 86% respectively, than in those people reporting no
symptoms, 17% and 50%, respectively. Smear microscopy also had a higher sensitivity among
those classified as WHO stage 3 or 4 as compared to WHO stage 1 or 2 (50% vs. 18%,
p = 0.001). However, while diagnostic testing sensitivity was higher for people with indicators
of more severe disease, neither microscopy nor Xpert had higher sensitivity to detect those
with TB who had died within 6 months of diagnosis as opposed to those who were still alive.
At the end of six months, 58 people (82%) with known outcome were alive and cured of
TB, while 13 people (18%) had died, including 4 who were smear-negative and died before
being diagnosed with culture-positive TB. Of those who were known to have died, 10 (73%)
were smear-negative and 6 (46%) were both smear- and Xpert-negative. The remaining 37
people had unknown vital status at 6 months, including 27 who were referred for TB treatment
elsewhere, 5 who were transferred to another site after starting treatment, 3 (2 smear-positive
and 1 smear-negative) who were lost to follow-up on treatment and 2 (both smear-negative)
who were lost to follow-up before starting treatment.
Of the 67 people who started TB treatment, the median time from the microscopy result to
treatment start was 17 days (IQR, 2–27 days). The time to start treatment for those with
Table 2. Tuberculosis prevalence and number needed to test (NNT) to identify one TB case among 940 people newly diagnosed with HIV, stratified by
characteristics.
Characteristic All Number of TB cases TB prevalence, %
(95% CI)
p-value Number needed to test, NNT
All patients 940 131 14 (12–16) 7
Age 35 years 510 63 12 (10–16) 0.13 8
>35 years 430 68 16 (13–20) 7
Sex Female 641 72 11 (9–14) <0.001 9
Male 299 59 20 (16–25) 5
CD4 count, cells/μL >350 387 25 7 (4–9) <0.001 14
200–349 212 26 12 (9–17) 8
100–199 128 24 19 (13–26) 5
<100 213 56 26 (21–33) 4
WHO stage 1 or 2 539 49 9 (7–12) <0.001 11
3 or 4 282 73 26 (21–31) 4
Number of symptoms No symptoms 128 10 8 (4–14) <0.001 13
Any 1 symptom 812 121 15 (13–18) 7
Any 2 symptoms 523 104 20 (17–24) 5
Any 3 symptoms 245 69 28 (23–34) 4
All 4 symptoms 75 33 44 (33–55) 2
Symptom Current cough 448 88 20 (16–24) <0.001 5
No current cough 492 43 9 (7–12) 11
Cough lasting2 weeks 228 49 22 (17–27) 0.34 5
Cough lasting <2 weeks 220 39 18 (13–23) 6
Current fever 220 54 25 (19–31) <0.001 4
No current fever 720 77 11 (9–13) 9
Night sweats, any 395 81 21 (17–25) <0.001 5
No night sweats 545 50 9 (7–12) 11
Weight loss 592 104 18 (15–21) <0.001 6
No weight loss 348 27 8 (5–11) 13
Symptoms including current cough, fever, night sweats, weight loss
https://doi.org/10.1371/journal.pone.0199634.t002
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smear-positive TB was 2 days (IQR, 1–3 days), while those with smear-negative TB started
treatment after 26 days (IQR, 20–32 days).
In this cohort, only one of the people with smear-negative TB was started on TB treatment
prior to the result of culture-positive TB; the other 68 people with smear-negative TB who
were started on TB treatment were all started as bacteriologically-confirmed TB cases follow-
ing the positive culture result.
Discussion
Among people newly diagnosed with HIV at a large HIV care and treatment center in Camer-
oon, 86% reported one or more symptoms of TB, and 14% (131/940) had culture-confirmed
pulmonary TB. The WHO symptom screen (current cough, fever, night sweats, weight loss)
was 92% sensitive and 15% specific to detect bacteriologically-confirmed TB in this popula-
tion. Direct smear microscopy detected 25% of people with culture-positive TB, concentrated
smear microscopy detected 36%, and retrospective testing with the Xpert MTB/RIF assay
detected 68%. Both smear microscopy and the Xpert MTB/RIF assay had higher sensitivity to
detect TB among people reporting more symptoms, but neither had good sensitivity to detect
TB among those people who died during follow-up. These findings suggest that while intensi-
fied screening and more sensitive diagnostics can add significant value to improving TB case
finding, these approaches should be combined with more intensive clinical follow-up of people
newly diagnosed with HIV in order to improve outcomes.
The proportion of people notified with clinically-diagnosed TB (as opposed to bacteriologi-
cally-confirmed TB) among all pulmonary TB cases in Cameroon is 26%, while it is 33% in the
African region and 43% globally.[16] This appears to reflect a more conservative approach to
the clinical diagnosis of TB in Cameroon than in other settings. This is particularly notable
Table 3. The sensitivities of microscopy and Xpert MTB/RIF assay among 108 people with culture-positive TB, stratified by number of symptoms reported, WHO
stage, CD4 count and vital status at 6 months.
Microscopy (conc.) Xpert MTB/RIF
% (95% CI) p- value % (95% CI) p-value
Total (n = 108) 36 (27–46) 68 (58–76)
Number of symptoms reported 0.03 0.09
No symptoms (n = 6) 17 (0–64) 50 (12–88)
1 symptom (n = 16) 19 (4–46) 69 (41–89)
2 symptoms (n = 27) 30 (14–50) 52 (32–71)
3 symptoms (n = 36) 32 (17–51) 68 (49–83)
4 symptoms (n = 28) 61 (41–79) 86 (67–96)
WHO stage (n = 100) 0.001 0.13
1 or 2 (n = 40) 18 (7–33) 58 (41–73)
3 or 4 (n = 60) 50 (37–63) 73 (60–84)
CD4 count (cells/uL) 0.1 0.4
200 (n = 42) 26 (14–42) 62 (46–76)
<200 (n = 66) 42 (30–55) 71 (59–81)
Patient vital status at 6 months (n = 71)† 0.06 0.52
Alive (n = 58) 45 (32–58) 67 (54–79)
Died (n = 13) 15 (2–45) 54 (26–80)
Microscopy results are for smears prepared from pellets after processing sputum for culture (the sensitivity of direct smear microscopy was 25%, 95% CI 18–34%).
†37 people did not have known vital status at 6 months because they had either been referred for treatment at another site or were lost to follow-up.
https://doi.org/10.1371/journal.pone.0199634.t003
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since the only TB diagnostic tool available in nearly the entire country is direct smear micros-
copy, which detected only 25% of culture-confirmed TB cases among people living with HIV
in this study.
The prevalence of bacteriologically-confirmed TB among people newly diagnosed with
HIV in this population was 14% (95%CI, 12–16%), which falls at the higher end of the range
reported from a meta-analysis of TB prevalence among people newly diagnosed with HIV at
antiretroviral and medical clinics (median 8.6%, range 3.6–24.7%).[1] In our study, the median
CD4 cell count of participants was relatively low (291 cells/uL) and 34% were classified as
WHO stage 3 or 4, which indicates that many of those newly diagnosed with HIV had been
infected for some time before their HIV diagnosis and were at a more advanced stage of HIV
disease. Since the time of the study, the approach to HIV treatment in Cameroon has changed
from initiation on antiretrovirals with advancing disease (CD4<350 cells/uL or WHO stage 3/
4) to the Test and Treat strategy. As testing increases and HIV infection is detected earlier in
the course of the disease, it is anticipated that the burden of TB among those newly diagnosed
with HIV will decrease[19] and clinical presentations of TB will shift towards less advanced
disease.[20]
The sensitivity of the Xpert MTB/RIF assay compared to TB culture in this population
(68%, 95% CI, 58–76) is somewhat lower than what has been reported previously for people
living with HIV in a meta-analysis (79%, 95%CI 70–86%)[21]. It is closer to the lower Xpert
sensitivity reported when compared to culture on two specimens rather than a single specimen
as the reference standard (76%, 95% CI, 66–84%)[22], which is expected since we used two
specimens for the culture reference standard in this work. While the sensitivity of the Xpert
MTB/RIF assay was 43% higher than direct microscopy and 32% higher than concentrated
microscopy among the patients in this study, Xpert testing still missed 32% of those with cul-
ture-positive pulmonary TB. Better performing diagnostic tests are urgently needed to con-
tinue to improve TB control efforts and improve patient outcomes.
People reporting more symptoms and those with higher WHO stage (3 or 4) were more
likely to have smear-positive TB than those reporting fewer symptoms or having less advanced
disease by WHO stage. These findings are in agreement with others who have reported
increased sputum mycobacterial load among people with TB having highly advanced HIV dis-
ease, as reflected in higher Xpert MTB/RIF sensitivity[7,23,24] and increasing sensitivity of
smear microscopy as CD4 cell count dropped below 150 cells/uL[25].
Of the 131 people with culture-confirmed TB, 88 (67%) reported current cough while 33
(25%) did not report cough but reported one or more of fever, night sweats or weight loss.
This highlights the importance of collecting sputum from all people reporting any symptoms
of TB, even those who do not report having cough and may need additional encouragement to
produce sputum. An additional 10 people (8% of all culture-positive TB cases) reported none
of the 4 symptoms, including 1 with smear-positive TB. Similar amounts of asymptomatic, cul-
ture-positive TB have been reported in other settings. [15,26,27]
This study had several limitations. Participants were enrolled only from a single site, and
although the Bamenda care and treatment center is one of the largest in the country, the gener-
alizability of the findings needs to be further assessed. While we performed a total of six spu-
tum cultures per person (one liquid and two solid cultures for each of two specimens), which
helps to provide a strong estimate of the prevalence of pulmonary TB in this population, we
did not perform culture on non-sputum specimens. The overall prevalence of TB is therefore
underestimated since a significant proportion of TB in people living with HIV is extrapulmon-
ary. In addition, our assessment of patient vital status at six months was limited due to high
rates of transfer (30%) and loss to follow up (5%).
TB in people newly diagnosed with HIV in Cameroon
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These findings highlight the need for the use of better diagnostic tools and algorithms to
diagnose TB among people living with HIV, as well as emphasis on careful follow-up of people
evaluated for TB in this setting. More work is needed to evaluate how to effectively follow-up
people with TB who have a negative lab test to ensure they are diagnosed and linked to treat-
ment as quickly as possible. These actions are necessary to facilitate faster detection of TB
cases and to improve patient outcomes, particularly among people living with HIV who have
smear and/or Xpert-negative TB.
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S1 Table. Sensitivity of TB detection by type of diagnostic method and specimen among 131
people newly diagnosed with HIV with culture-confirmed TB (Table A). Comparison of
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